CDH Investments

SharkNinja Announces Pricing of Secondary Offering of Ordinary Shares

Retrieved on: 
Wednesday, December 6, 2023
Consumer Electronics, Retail, Other Consumer, Consumer, Technology, Home Goods, Other Technology, Sale, NYSE, Madison Avenue, William Blair & Company, Telephone, Attention, Security (finance), J. P. Morgan, Jefferies, Varick Street, Morgan Stanley, CDH, Investment, 2nd Floor, Jefferies Group, Prospectus, Guggenheim Partners, Guggenheim, CDH Investments, SharkNinja, L.L.C

SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today announced the pricing of the previously announced secondary offering of 6,095,169 ordinary shares of SharkNinja by certain selling shareholders affiliated with Xuning Wang and CDH Investments (collectively, the “Selling Shareholders”) at a price to the public of $47.00 per ordinary share.

Key Points: 
  • SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today announced the pricing of the previously announced secondary offering of 6,095,169 ordinary shares of SharkNinja by certain selling shareholders affiliated with Xuning Wang and CDH Investments (collectively, the “Selling Shareholders”) at a price to the public of $47.00 per ordinary share.
  • The Selling Shareholder affiliated with CDH Investments has granted the underwriters a 30-day option to purchase up to an additional 914,275 ordinary shares of SharkNinja.
  • SharkNinja is not selling any ordinary shares in the offering and will not receive any of the proceeds from the sale.
  • Goldman Sachs & Co. LLC, J.P. Morgan, Jefferies and Morgan Stanley are acting as joint lead book-running managers for the offering.

SharkNinja Announces Launch of Secondary Offering of Ordinary Shares

Retrieved on: 
Monday, December 4, 2023
Other Consumer, Technology, Other Retail, Other Technology, Home Goods, Lifestyle, Consumer, Retail, Consumer Electronics, Sale, NYSE, Madison Avenue, William Blair & Company, Telephone, Attention, Security (finance), J. P. Morgan, Form, Jefferies, Varick Street, Morgan Stanley, CDH, Investment, 2nd Floor, Jefferies Group, SEC filing, Prospectus, Guggenheim Partners, Guggenheim, CDH Investments, SharkNinja, L.L.C

Additionally, the Selling Shareholder affiliated with CDH Investments intends to grant the underwriters a 30-day option to purchase up to an additional 841,896 ordinary shares of SharkNinja.

Key Points: 
  • Additionally, the Selling Shareholder affiliated with CDH Investments intends to grant the underwriters a 30-day option to purchase up to an additional 841,896 ordinary shares of SharkNinja.
  • SharkNinja is not selling any ordinary shares in the offering and will not receive any of the proceeds from the sale.
  • Goldman Sachs & Co. LLC, J.P. Morgan, Jefferies and Morgan Stanley are acting as joint lead book-running managers for the proposed offering.
  • The proposed offering of these securities will be made only by means of a prospectus.

Spear Bio, developer of the next-generation ultrasensitive immunodiagnostics and proteomics platform, completes raise of tens of millions of US dollars with oversubscribed Seed Prime

Retrieved on: 
Wednesday, November 29, 2023
Microfluidics, DBS, Immunity, Research, DNA, Conditional sentence, Proteomics, Investment, Protein, Reproductive success, Disease, CDH, Patient, Multimedia, Neurology, Laboratory, SPEAR, Harvard University, Infection, COVID-19, Workflow, Ultra, Biomarker, Real-time, Wyss Institute, ELISA, Partnership, CDH Investments, Pharmaceutical industry, Medical imaging, Hunting

The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.

Key Points: 
  • The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.
  • Spear Bio was co-founded in March 2021 as a spin-off from Harvard University's Wyss Institute by Professor Peng Yin and Dr. Feng Xuan.
  • The company is developing the next generation ultrasensitive immunodiagnostics and proteomics platform based on a breakthrough technology its founders developed and licensed from Harvard University: the Successive Proximity Extension Amplification Reaction, or SPEAR.
  • Spear Bio is now focused on bringing to market ultrasensitive immunoassays for areas such as neurology, immunology, and oncology.

KuCoin Labs Launches Incubation Program to Accelerate Builders

Retrieved on: 
Wednesday, December 21, 2022
Professional Services, Blockchain, NFT, Technology, Cryptocurrency, Web3, Finance, Crypto, Mentorship, CDH, Matrix Partners, Multimedia, Lecture, Growth, CDH Investments, NFT, Vertu, Marketing, Cryptocurrency, Metaverse

KuCoin Labs, the incubation and research arm of KuCoin, has announced the launch of the long-term incubation program, to accelerate builders and enable a sustainable growth and success in the blockchain space.

Key Points: 
  • KuCoin Labs, the incubation and research arm of KuCoin, has announced the launch of the long-term incubation program, to accelerate builders and enable a sustainable growth and success in the blockchain space.
  • The builders who are interested in the incubation program could apply online here , to get diversified supports from KuCoin labs and the mentors.
  • There are five main components of the incubation program:
    KuCoin Labs' Incubation Program will last for eight weeks.
  • KuCoin Labs Incubation Program also receives supports from MoonRock Capital, Vertu, CDH Investment, IOBC Capital, Matrix Partners and other leading institutions.

Sharing Economy International Inc: $30 million to be raised for investing in naked eye 3D technology

Retrieved on: 
Thursday, April 7, 2022
Sequoia Capital, The Devil's Share (film), Ecology, Television, Group, 3D, Growth, Xiaomi, Research, GAMA, Harte Hanks, Software, Industry, Technology, Architecture, CDH, CDH Investments, Efficiency, PE, Algorithm, Video game

Sharing Economy International Inc is a company established in 1987.

Key Points: 
  • Sharing Economy International Inc is a company established in 1987.
  • Since the second quarter of 2017, the Group has focused on technology and the global sharing economy market based on the global market, advocating green economy and boosting the development of the global sharing economy by developing online platforms and leasing business cooperation.
  • Hanking Fund is a private equity fund operated and managed by a family office in a professional way for wealthy families.
  • Hanking funds intends to make strategic investments to SEII with a total size of no more than US$30 million during 2 year period.

RootPath Launches, Elevating Throughput of Gene Function Interrogation by Orders of Magnitude

Retrieved on: 
Monday, March 21, 2022
Biotechnology, Genetics, Health, Oncology, Cell, Keystone, TCR, Partner, DNA, Synthetic biology, Patient, Â, CEO, Entrepreneurship, CDH Investments, Technology, Biology, TIL, Investment, CDH, Gene, HLA, Pathfinder, Vaccine, Fine chemical

RootPath, a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, launched today, debuting technology that enables unprecedented access to long synthetic genes and their functional readouts with multiple applications.

Key Points: 
  • RootPath, a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, launched today, debuting technology that enables unprecedented access to long synthetic genes and their functional readouts with multiple applications.
  • We are grateful to present on our limitless gene synthesis capability at the Keystone conference.
  • We are pursuing its application in T cell therapies internally and in many other fields through collaborations.
  • RootPath is a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude.

IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

Retrieved on: 
Thursday, September 16, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CD5, Semiconductor, Artificial intelligence, NDA, CEO, Patient, BCMA, Series, Clinical trial, IND, Maxwell, Investment, CDH, RRMM, NMPA, Degenerative disease, CAR, CMO, CDH Investments, Trust, China Everbright Limited, Pharmaceutical industry, Fine chemical, CDH Baifu, IASO Bio, CDH BAIFU, IASO BIO

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicines, today announced the completion of $108 million Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.

Key Points: 
  • IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicines, today announced the completion of $108 million Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
  • Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.
  • The clinical development of these three innovative products marks the full coverage of our products in plasma cell, B cell, and T cell malignancies.
  • IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases.

InferVision Completes Series D2 Financing Round Led by Goldman Sachs Asset Management

Retrieved on: 
Friday, August 13, 2021
D2, Stop TB Partnership, Goldman Sachs, China Construction Bank, Pneumonia, UNOPS, CE, Tuberculosis, National Medical Products Administration, Food and Drug Administration, Sequoia Capital, United Nations Office for Project Services, GDF, CDH, Certification, Food, Deep learning, United Nations, COVID-19, Quality control, Technology, PMDA, Research, Trust, Investment, Medicines and Healthcare products Regulatory Agency, FDA, A.I, Patient, CDH Investments, Efficiency, European Union, Union, AI, Hospital, Diagnosis, Qiming Venture Partners, Health, CK, Solution, Medical device

PHILADELPHIA, Aug. 13, 2021 /PRNewswire/ --InferVision, a medical artificial intelligence (AI) provider specializing in the clinical application of AI and deep learning technologies announced the completion of its Series D2 financing led by Goldman Sachs Asset Management.

Key Points: 
  • PHILADELPHIA, Aug. 13, 2021 /PRNewswire/ --InferVision, a medical artificial intelligence (AI) provider specializing in the clinical application of AI and deep learning technologies announced the completion of its Series D2 financing led by Goldman Sachs Asset Management.
  • The company has raised around US$140 million in total from Series D1 and D2 financing.
  • Using AI and deep learning technologies, InferVision is developing platforms including AI application management and data mining & research.
  • "We are excited to have a proven, global investor like Goldman Sachs lead this latest round of financing.

Noah Holdings Limited to Announce Second Quarter 2021 Financial Results on Tuesday, August 17, 2021

Retrieved on: 
Tuesday, August 3, 2021
Finance, Investment, Financial services, Institutional investors, Primary dealers, Subprime mortgage crisis, CDH Investments

Noah Holdings Limited (NYSE: NOAH, BBB-) is a leading and pioneer wealth management service provider in China offering comprehensive one-stop advisory services on global investment and asset allocation primarily for high net worth investors.

Key Points: 
  • Noah Holdings Limited (NYSE: NOAH, BBB-) is a leading and pioneer wealth management service provider in China offering comprehensive one-stop advisory services on global investment and asset allocation primarily for high net worth investors.
  • In the first quarter of 2021, Noah distributed RMB27.1 billion (US$4.1 billion) of investment products.
  • Through Gopher Asset Management, Noah had assets under management of RMB154.1 billion (US$23.5 billion) as of March 31, 2021.
  • Noah's wealth management business primarily distributes private equity, public securities and insurance products denominated in RMB and other currencies.

Shore Capital Partners Total Assets Under Management (AUM) Surpasses $2 Billion

Retrieved on: 
Thursday, July 15, 2021
Professional services, Finance, Finance, Money, Investment, Corporate finance, Private equity, Alternative investment management companies, Berkshire Partners, CDH Investments

Shore Capital Partners (Shore or the Firm), a strategic private equity firm focused on microcap investing in the healthcare, food and beverage, business services, and real estate industries, with offices in Chicago and Nashville, announced the first and only closings of its fourth institutional healthcare private equity fund, Shore Capital Healthcare Partners Fund IV (HC Fund IV), its first business services fund, Shore Capital Business Services Partners Fund I (BS Fund I), and its first real estate fund, Shore Capital Real Estate Partners Fund I (RE Fund I).

Key Points: 
  • Shore Capital Partners (Shore or the Firm), a strategic private equity firm focused on microcap investing in the healthcare, food and beverage, business services, and real estate industries, with offices in Chicago and Nashville, announced the first and only closings of its fourth institutional healthcare private equity fund, Shore Capital Healthcare Partners Fund IV (HC Fund IV), its first business services fund, Shore Capital Business Services Partners Fund I (BS Fund I), and its first real estate fund, Shore Capital Real Estate Partners Fund I (RE Fund I).
  • With these respective closings totaling $686 million, Shore now manages a total committed capital base of $2 billion.
  • Shore Capital Healthcare Partners Fund IV surpassed its original target of $300 million and was substantially oversubscribed.
  • Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value for shareholders.